Allergan plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Cash Flows From Operating Activities:
Net (loss) / income
Warner Chilcott Limited
Total net (loss) / income
Reconciliation to net cash provided by operating activities:
Depreciation
Warner Chilcott Limited
Total depreciation
Amortization
Warner Chilcott Limited
Total amortization
Provision for inventory reserve
Warner Chilcott Limited
Total provision for inventory reserve
Share-based compensation
Warner Chilcott Limited
Total share-based compensation
Deferred income tax benefit
Warner Chilcott Limited
Total deferred income tax benefit
Pre-tax gain on sale of businesses to Teva
Teva
Warner Chilcott Limited
Total pre-tax gain on sale of businesses to Teva
Non-cash tax effect of gain on sale of businesses to Teva
Teva
Warner Chilcott Limited
Total non-cash tax effect of gain on sale of businesses to Teva
Goodwill impairments
Warner Chilcott Limited
Total goodwill impairments
In-process research and development impairments
Warner Chilcott Limited
Total in-process research and development impairments
Loss on asset sales and impairments, net
Warner Chilcott Limited
Total loss on asset sales and impairments, net
Net income impact of other-than-temporary loss on investment in Teva securities
Charge to settle Teva related matters
Warner Chilcott Limited
Total charge to settle Teva related matters
(Gain) loss on sale of Teva securities, net
Warner Chilcott Limited
Total (Gain) loss on sale of Teva securities, net
Amortization of inventory step-up
Warner Chilcott Limited
Total amortization of inventory step-up
Gain on sale of businesses
Warner Chilcott Limited
Total gain on sale of businesses
Non-cash extinguishment of debt
Warner Chilcott Limited
Total non-cash extinguishment of debt
Cash (discount) / charge related to extinguishment of debt
Warner Chilcott Limited
Total cash (discount) / charge related to extinguishment of debt
Amortization of deferred financing costs
Warner Chilcott Limited
Total amortization of deferred financing costs
Excess tax benefit from stock-based compensation
Amortization of right of use assets
Warner Chilcott Limited
Total amortization of right of use assets
Contingent consideration adjustments, including accretion
Warner Chilcott Limited
Total contingent consideration adjustments, including accretion
Other, net
Warner Chilcott Limited
Total other, net

Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net
Warner Chilcott Limited
Total decrease / (increase) in accounts receivable, net
Decrease / (increase) in inventories
Warner Chilcott Limited
Total decrease / (increase) in inventories
Decrease / (increase) in prepaid expenses and other current assets
Warner Chilcott Limited
Total decrease / (increase) in prepaid expenses and other current assets
Increase / (decrease) in accounts payable and accrued expenses
Warner Chilcott Limited
Total increase / (decrease) in accounts payable and accrued expenses
Increase / (decrease) in income and other taxes payable
Warner Chilcott Limited
Total increase / (decrease) in income and other taxes payable
Increase / (decrease) in other assets and liabilities
Warner Chilcott Limited
Total increase / (decrease) in other assets and liabilities
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents
Net cash provided by operating activities
Warner Chilcott Limited
Total net cash provided by operating activities
Cash Flows From Investing Activities:
Additions to property, plant and equipment
Warner Chilcott Limited
Total additions to property, plant and equipment
Additions to product rights and other intangibles
Warner Chilcott Limited
Total additions to product rights and other intangibles
Additions to investments
Warner Chilcott Limited
Total additions to investments
Proceeds from sale of investments and other assets
Warner Chilcott Limited
Total proceeds from sale of investments and other assets
Loans to Parent
Loans to Parents
Payments to settle Teva related matters
Proceeds from sales of property, plant and equipment
Warner Chilcott Limited
Total proceeds from sales of property, plant and equipment
Acquisitions of businesses, net of cash acquired
Warner Chilcott Limited
Total acquisitions of businesses, net of cash acquired
Net cash provided by / (used in) investing activities
Warner Chilcott Limited
Total net cash provided by / (used in) investing activities
Sale of businesses to Teva
Teva
Warner Chilcott Limited
Total sale of businesses to Teva

Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility
Warner Chilcott Limited
Total proceeds from borrowings of long-term indebtedness, including credit facility
Proceeds from borrowings on credit facility and other
Warner Chilcott Limited
Total proceeds from borrowings on credit facility and other
Payments on debt, including capital lease obligations and credit facility
Warner Chilcott Limited
Total payments on debt, including capital lease obligations and credit facility
Proceeds from issuance of preferred shares
Proceeds from issuance of ordinary shares
Debt issuance and other financing costs
Warner Chilcott Limited
Total debt issuance and other financing costs
Cash charge related to extinguishment of debt
Warner Chilcott Limited
Total cash charge related to extinguishment of debt
Payments of contingent consideration and other financing
Warner Chilcott Limited
Total payments of contingent consideration and other financing
Proceeds from stock plans
Proceeds from forward sale of Teva securities
Warner Chilcott Limited
Total proceeds from forward sale of Teva securities
Payments to settle Teva related matters
Repurchase of ordinary shares
Dividends paid
Excess tax benefit from stock-based compensation
Dividend to Parents
Contribution from Parent
Net cash (used in) financing activities
Warner Chilcott Limited
Total net cash (used in) financing activities

Effect of currency exchange rate changes on cash and cash equivalents
Warner Chilcott Limited
Total effect of currency exchange rate changes on cash and cash equivalents
Net (decrease) / increase in cash and cash equivalents
Warner Chilcott Limited
Total net (decrease) / increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Warner Chilcott Limited
Total cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Warner Chilcott Limited
Total cash and cash equivalents at end of period
Supplemental Disclosures of Cash Flow Information:
Cash paid / (received) during the year for:
Income taxes other, net of refunds
Warner Chilcott Limited
Total income taxes other, net of refunds
Interest
Warner Chilcott Limited
Total interest
Schedule of Non-Cash Investing and Financing Activities:
Conversion of mandatory convertible preferred shares
Non-cash equity issuance
Allergan, Inc.
Kythera
Teva
Zeltiq

Settlement of secured financing
Warner Chilcott Limited
Total settlement of secured financing
Receipt of ordinary shares in connection with the sale of the generics business
Non-cash dividends to Parents
Dividends accrued

Comments